Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Denali Therapeutics ( (DNLI) ) just unveiled an announcement.
Denali Therapeutics announced that its Phase 2/3 trial of DNL343, intended to treat amyotrophic lateral sclerosis (ALS), did not meet its primary or key secondary endpoints of efficacy in slowing disease progression over 24 weeks. Despite these results, the drug was found to be safe and well-tolerated, and further analysis, including biomarker and subgroup assessments, is expected later in 2025. The company remains committed to understanding the effects of DNL343 and advancing ALS research, highlighting the need for better treatment options and the value of data collected from the trial.
More about Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company focused on developing therapies for neurodegenerative and lysosomal storage diseases. The company aims to create treatments that can cross the blood-brain barrier and uses genetically validated targets and biomarkers for development.
YTD Price Performance: 2.02%
Average Trading Volume: 831,902
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.06B
Find detailed analytics on DNLI stock on TipRanks’ Stock Analysis page.
